110 related articles for article (PubMed ID: 23324806)
1. The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3'-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients.
Sebio A; Paré L; Páez D; Salazar J; González A; Sala N; del Río E; Martín-Richard M; Tobeña M; Barnadas A; Baiget M
Pharmacogenet Genomics; 2013 Mar; 23(3):142-7. PubMed ID: 23324806
[TBL] [Abstract][Full Text] [Related]
2. Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan.
Graziano F; Canestrari E; Loupakis F; Ruzzo A; Galluccio N; Santini D; Rocchi M; Vincenzi B; Salvatore L; Cremolini C; Spoto C; Catalano V; D'Emidio S; Giordani P; Tonini G; Falcone A; Magnani M
Pharmacogenomics J; 2010 Oct; 10(5):458-64. PubMed ID: 20177422
[TBL] [Abstract][Full Text] [Related]
3. A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy.
Saridaki Z; Weidhaas JB; Lenz HJ; Laurent-Puig P; Jacobs B; De Schutter J; De Roock W; Salzman DW; Zhang W; Yang D; Pilati C; Bouché O; Piessevaux H; Tejpar S
Clin Cancer Res; 2014 Sep; 20(17):4499-4510. PubMed ID: 25183481
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the prevalence of KRAS-LCS6 polymorphism (rs61764370) within different tumour types (colorectal, breast, non-small cell lung cancer and brain tumours). A study of the Czech population.
Uvirova M; Simova J; Kubova B; Dvorackova N; Tomaskova H; Sedivcova M; Dite P
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Sep; 159(3):466-71. PubMed ID: 26077004
[TBL] [Abstract][Full Text] [Related]
5. A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy.
Zhang W; Winder T; Ning Y; Pohl A; Yang D; Kahn M; Lurje G; LaBonte MJ; Wilson PM; Gordon MA; Hu-Lieskovan S; Mauro DJ; Langer C; Rowinsky EK; Lenz HJ
Ann Oncol; 2011 Jan; 22(1):104-109. PubMed ID: 20603437
[TBL] [Abstract][Full Text] [Related]
6. Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab.
Kjersem JB; Ikdahl T; Guren T; Skovlund E; Sorbye H; Hamfjord J; Pfeiffer P; Glimelius B; Kersten C; Solvang H; Tveit KM; Kure EH
BMC Cancer; 2012 Nov; 12():534. PubMed ID: 23167843
[TBL] [Abstract][Full Text] [Related]
7. High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease.
Ruzzo A; Graziano F; Vincenzi B; Canestrari E; Perrone G; Galluccio N; Catalano V; Loupakis F; Rabitti C; Santini D; Tonini G; Fiorentini G; Rossi D; Falcone A; Magnani M
Oncologist; 2012; 17(6):823-9. PubMed ID: 22584434
[TBL] [Abstract][Full Text] [Related]
8. Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial).
Sha D; Lee AM; Shi Q; Alberts SR; Sargent DJ; Sinicrope FA; Diasio RB
Clin Cancer Res; 2014 Jun; 20(12):3319-27. PubMed ID: 24727325
[TBL] [Abstract][Full Text] [Related]
9. Let-7 microRNA-binding-site polymorphism in the 3'UTR of KRAS and colorectal cancer outcome: a systematic review and meta-analysis.
Langevin SM; Christensen BC
Cancer Med; 2014 Oct; 3(5):1385-95. PubMed ID: 24890702
[TBL] [Abstract][Full Text] [Related]
10. A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer.
Smits KM; Paranjape T; Nallur S; Wouters KA; Weijenberg MP; Schouten LJ; van den Brandt PA; Bosman FT; Weidhaas JB; van Engeland M
Clin Cancer Res; 2011 Dec; 17(24):7723-31. PubMed ID: 21994416
[TBL] [Abstract][Full Text] [Related]
11. EGFR fluorescence in situ hybridization pattern of chromosome 7 disomy predicts resistance to cetuximab in KRAS wild-type metastatic colorectal cancer patients.
Li YH; Wang F; Shen L; Deng YM; Shao Q; Feng F; An X; Wang FH; Wang ZQ; Xu RH; Shao JY
Clin Cancer Res; 2011 Jan; 17(2):382-90. PubMed ID: 20884623
[TBL] [Abstract][Full Text] [Related]
12. Targeted knock-in of the polymorphism rs61764370 does not affect KRAS expression but reduces let-7 levels.
Crowley EH; Arena S; Lamba S; Di Nicolantonio F; Bardelli A
Hum Mutat; 2014 Feb; 35(2):208-14. PubMed ID: 24282149
[TBL] [Abstract][Full Text] [Related]
13. Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab.
Lurje G; Nagashima F; Zhang W; Yang D; Chang HM; Gordon MA; El-Khoueiry A; Husain H; Wilson PM; Ladner RD; Mauro DJ; Langer C; Rowinsky EK; Lenz HJ
Clin Cancer Res; 2008 Dec; 14(23):7884-95. PubMed ID: 19047118
[TBL] [Abstract][Full Text] [Related]
14. The let-7 microRNA binding site variant in KRAS as a predictive biomarker for head and neck cancer patients with lymph node metastasis.
Ulusan M; Sen S; Yilmazer R; Dalay N; Demokan S
Pathol Res Pract; 2022 Nov; 239():154147. PubMed ID: 36228348
[TBL] [Abstract][Full Text] [Related]
15. EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: implications for targeted therapy.
Berg M; Soreide K
Discov Med; 2012 Sep; 14(76):207-14. PubMed ID: 23021375
[TBL] [Abstract][Full Text] [Related]
16. A single nucleotide polymorphism in the 3'-untranslated region of the KRAS gene disrupts the interaction with let-7a and enhances the metastatic potential of osteosarcoma cells.
Zhang S; Hou C; Li G; Zhong Y; Zhang J; Guo X; Li B; Bi Z; Shao M
Int J Mol Med; 2016 Sep; 38(3):919-26. PubMed ID: 27430246
[TBL] [Abstract][Full Text] [Related]
17. No evidence for genetic association with the let-7 microRNA-binding site or other common KRAS variants in risk of endometriosis.
Luong HT; Nyholt DR; Painter JN; Chapman B; Kennedy S; Treloar SA; Zondervan KT; Montgomery GW
Hum Reprod; 2012 Dec; 27(12):3616-21. PubMed ID: 23010532
[TBL] [Abstract][Full Text] [Related]
18. A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk.
Chin LJ; Ratner E; Leng S; Zhai R; Nallur S; Babar I; Muller RU; Straka E; Su L; Burki EA; Crowell RE; Patel R; Kulkarni T; Homer R; Zelterman D; Kidd KK; Zhu Y; Christiani DC; Belinsky SA; Slack FJ; Weidhaas JB
Cancer Res; 2008 Oct; 68(20):8535-40. PubMed ID: 18922928
[TBL] [Abstract][Full Text] [Related]
19. A let-7 microRNA-binding site polymorphism in the KRAS 3' UTR is associated with reduced survival in oral cancers.
Christensen BC; Moyer BJ; Avissar M; Ouellet LG; Plaza SL; McClean MD; Marsit CJ; Kelsey KT
Carcinogenesis; 2009 Jun; 30(6):1003-7. PubMed ID: 19380522
[TBL] [Abstract][Full Text] [Related]
20. Association of a let-7 KRAS rs712 polymorphism with the risk of breast cancer.
Huang X; Yang Y; Guo Y; Cao ZL; Cui ZW; Hu TC; Gao LB
Genet Mol Res; 2015 Dec; 14(4):16913-20. PubMed ID: 26681038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
